Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785939 | 1.00 | MEN1 (0.52) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL803539 | 0.92 | MEN1 (0.52) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL2817155 | 0.86 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL2817156 | 0.86 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL785763 | 0.82 | WDR5 (0.43) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL785764 | 0.82 | WDR5 (0.43) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL2817638 | 0.80 | PDE4A (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL2817640 | 0.80 | PDE4A (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL784366 | 0.80 | MEN1 (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL485045 | 0.79 | MEN1 (0.51) | MEN1KMT2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | MEN1 2563/4885KMT2A 2222/4885PDE4A 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.